GHK-Cu + BPC-157
The same two compounds, without a seller fixing the ratio.
GHK-Cu makes up 71 percent of a GLOW vial and 63 percent of a KLOW vial, and you cannot change either. Bought as a pair, you set the balance. It is also the cheapest way into this category, at about $39 for both.
Healing that shows, at the lowest entry price in the category.
People reach for this after surgery, for scarring, for skin that has lost firmness, and for wounds that are healing slowly. GHK-Cu is the draw. It has the most human evidence of anything in this category. People losing weight on a GLP-1 drug now pair it with retatrutide for the same reason. It is also paired with thymosin alpha-1, alongside GHK-Cu or on its own, and with epitalon in the broader longevity stack. It is also already in mainstream cosmetics, which almost nothing else here can say.
BPC-157 covers the repair side, and it is the compound most people in peptides start with.
What separates this pairing from the blends is control. GLOW is these two plus TB-500. KLOW adds KPV on top. Both come premixed at a ratio the seller chose, and in both cases that ratio is dominated by GHK-Cu.
Four benefits, and how well each one holds up.
The bottom row is the only thing on this page that is certain, and it is the practical reason to buy the pair separately rather than premixed.
Three questions, answered before anything else.
In a blend, most of what you buy is one compound.
Where vendors publish the amounts, the standard formulations break down like this.[1]
There is a real argument for the blend ratios. GHK-Cu is a bulkier molecule and the split may reflect what the makers think it takes to do anything. Nobody has published a rationale, so the reasoning is not available to check.
There is a real argument for blends generally. One vial means mixing powder once instead of twice. One thing to store. Fewer punctures, and fewer chances to contaminate something. Buying the pair separately trades that convenience for control over the balance, and saves money.
Good data, on a route almost nobody in this stack uses.
GHK-Cu has more human evidence than almost anything in the skin category, and that is worth saying plainly because it is rare here.
Nearly all of it is topical, meaning creams and serums put on the skin and measured there. People in this stack are injecting it. Injecting means a different dose reaching different tissue, and no trial has tested whether the topical results carry across.
The mechanism argument for why they should is reasonable and has never been checked. That leaves a compound with genuinely good evidence being used in a way its evidence does not cover, which is a different situation from a compound with no evidence at all.
One handling note matters here more than in a blend. GHK-Cu is sensitive to light, and keeping it in its own vial means that is handled separately rather than alongside everything else.
A human trial was run and the results never came out.
A Croatian company called Pliva took BPC-157 into human testing for inflammatory bowel disease under the designation PL 14736. Healthy volunteers took it first with no safety problems reported. Then came a Phase 2 trial in ulcerative colitis, a disease that inflames the large bowel. The results have never been published.[2]
As of 2026, no large human trial of BPC-157 has been published for any use. By large we mean the later stages of drug testing. Hundreds of people, split between the compound and a placebo by chance, so the comparison is fair.[3] The animal work is substantial and consistent across tendon, ligament, gut and surgical healing models, and animal results have translated badly to people for this class of compound.[3]
The gut stack page covers that trial history in more detail. No study has given GHK-Cu and BPC-157 together in people or animals. We looked and came up empty. A formal systematic review might find more, and if you know of a trial we will correct this.
Neither is approved, and one advantage is worth noting.
Neither compound has FDA approval for any use. BPC-157 went through a Pharmacy Compounding Advisory Committee review in July 2026. GHK-Cu is widely sold in cosmetics, and putting it on skin and injecting it are different regulatory questions.
One thing this pairing avoids: TB-500 is not in it. TB-500 is in both GLOW and KLOW, and it is listed under section S2 of the 2026 prohibited list from WADA, the World Anti-Doping Agency, banned in competition and out of it. A blend takes on the strictest status of anything inside it, so any tested athlete taking GLOW or KLOW has committed a doping violation. This pair does not carry that problem.
Two things specific to this pair.
Neither compound has a registered clinical trial with systematic side effect collection, so there are no placebo-controlled rates to quote here the way there are for the weight loss compounds. Both are widely described as well tolerated, and that rests on an absence of reports rather than on anyone counting.
GHK-Cu carries copper, and that is the part worth understanding. The copper is what makes it work: the peptide binds a copper ion and delivers it, which is how it signals collagen production. It is also why the compound is blue in solution. Topical use has a long safety record. Injecting means the copper goes somewhere different, and nobody has published what happens to copper levels over a long course.
The handling point matters more here than in a blend. GHK-Cu degrades in light, so it is kept in its own vial, stored dark, and not mixed with anything else. Buying the pair separately means that is handled properly by default rather than depending on how a seller packaged it.
BPC-157 has the largest animal literature of any compound on this site. Tendons, ligaments, gut, and healing after surgery, consistent across many studies. An early human safety study also found it well tolerated.[2]
What people ask about this pair
Is this just GLOW without TB-500?
In composition, yes. In practice there are two differences. You set the ratio between the two compounds instead of accepting the seller's, and in a GLOW vial that ratio is 71 percent GHK-Cu. And TB-500 is the compound that makes GLOW a doping violation, so leaving it out changes the sporting position entirely.
Does injected GHK-Cu work like the skincare version?
Unknown. GHK-Cu has more human evidence than almost anything in the skin category, and nearly all of it is topical, meaning creams and serums put on the skin and measured there. Injecting means a different dose reaching different tissue, and no trial has tested whether the results transfer. The mechanism argument for why they should has never been checked.
Should I buy the blend instead?
The blend gives you one reconstitution, one thing to store and fewer chances to contaminate something, which is a genuine advantage. It also fixes the ratio permanently and costs more, with GLOW starting at $44.00 against $38.68 for this pair. If you want a different balance between the two compounds, the blend cannot give it to you.
Can they be mixed in one syringe?
GHK-Cu is sensitive to light and is usually kept in its own vial rather than mixed with anything else. That is the main practical reason people who buy the pair keep them separate even when convenience would suggest otherwise.
Why is GHK-Cu blue?
Because it is carrying copper. The peptide binds a copper ion and delivers it, and that delivery is how it signals collagen production rather than an incidental feature. A blue tint in solution is expected. Topical use has a long safety record behind it. Injecting means the copper reaches different tissue, and nobody has published what happens to copper levels over a long course.
Has the combination been studied?
No study we could find has given both compounds together, in people or in animals. Each has its own literature and the pairing has none. Compare against the other stacks.
What this page is built on
- 01Peptide Decoding vendor pricing data, 12 September 2026. Lowest in-stock single-compound listings: GHK-Cu $19.49, BPC-157 $19.19. Blend composition parsed from vendor listing strings: GLOW 70 mg at 50/10/10, KLOW 80 mg at 50/10/10/10.
- 02BPC-157 as PL 14736 under Pliva: Phase 1 safety in healthy volunteers, Phase 2 in ulcerative colitis, results unpublished.
- 03No published Phase 2 or Phase 3 randomized controlled trials of BPC-157 in humans for any indication as of 2026, and the note on poor historical animal-to-human translation for peptide healing compounds.